About Us: Leadership Team

Robert E. Henry

Chief Executive Officer
MBA
{ View Bio }
As Chief Executive Officer, Robert Henry is leading another healthcare turnaround success story; his experience in growing, building, and rejuvenating healthcare companies is being applied at Pierian Biosciences. He has excelled as a Business Development leader, President and CEO/board member with extensive qualifications in operational and financial management, management restructuring, contract negotiations, and international governance. Robert Henry joined DiaTech Oncology (now Pierian) in 2013 to take the company to the next level in regard to being a thought leader and the significant player in the personalized cancer care market. Robert joined DiaTech with more than 25 years of healthcare management experience and in developing, implementing and evaluating new opportunities in managed care. He served as SVP of Development at Symbion, Inc. and was the Chief Executive Officer at Dialog Health. Prior to that he served as the President and Chief Executive Officer of American Endoscopy Services (AES) from 1997 to 2010. Prior to AES, he served as the Chief Operating Officer of Physician Alliances.  Mr. Henry holds an MBA from the Owen Graduate School of Management at Vanderbilt University and a B.S., Business Administration-Finance from the University of Tennessee.

Lyn W. Cates

Head Corp Operations

{ View Bio }

With a broad range of experience from Fortune 50 to start-ups and turn-arounds, Ms. Lyn Cates arrives at DiaTech with more than 25 years of healthcare technology operations leadership and experience. Lyn has led almost every aspect of operational and technology teams including analysis, design, development, project management, and implementation with a singular goal of supporting the business through on time, on budget implementations. Lyn’s experience includes major healthcare organization such as Informatics Corporation of America (ICA), Hospital Corporation of America (HCA) and QualiFacts, as well as consulting experience in all facets of healthcare information technology.

Mark S. Gelder

Chief Medical Officer
MD

{ View Bio }

Dr. Mark Gelder brings with him more than 25 years of oncology clinical trial and drug development experience to DiaTech Oncology and is board certified in Internal Medicine, Obstetrics and Gynecology and Gynecologic Oncology. As an experienced researcher and clinician, he has significant regulatory experience working closely with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in various leadership roles at blue-chip pharmaceutical companies such as Pfizer, Wyeth, Bayer, GE Healthcare, Heron Therapeutics and Inovio Pharmaceuticals.

At Colgate University, Mark began his journey into medicine, majoring in Biochemistry and Molecular Biology and went on to the University of Virginia, School of Medicine where he graduated with honors (AOA). Following his residency in Internal Medicine at the University of Virginia, he completed an additional residency in Obstetrics and Gynecology and a fellowship in Gynecologic Oncology at the University of Alabama, Birmingham.

Following his training, he served as an attending physician in Gynecologic Oncology at the University of Florida College of Medicine where he was promoted to Director within the Division of Gynecologic Oncology. Dr. Gelder later joined a multi-specialty oncology group in Charlotte, NC as the Director of Gynecologic Oncology at Presbyterian Cancer Center.

Throughout his years in practice, Mark has been active in clinical research and a member of the Gynecologic Oncology Group (GOG). Mark has been a member of several medical and oncology organizations and is currently a fellow of the American College of Obstetrics and Gynecology.

J. Yvette Payne

Head Clinical & Platform Operations
APRN, MS, MBA

{ View Bio }

Ms. Yvette Payne is a recognized expert in the field of oncology with more than 30 years of experience in clinical operations and medical affairs. As a professional well-regarded in her field, Yvette has a proven track record for building highly successful and dynamic teams at various pharmaceutical companies such as Ortho-Biotech, a Johnson & Johnson company, Cephalon and Heron Therapeutics. In addition to earning leadership roles at some of the largest pharmaceutical giants, Yvette has also served as an independent consultant for a number of multi-national pharmaceutical and biotechnology companies in the development of scientific and clinical strategy, clinical operations, training and education.

Yvette obtained both Bachelor of Science and Master of Science degrees from the University of Texas Health Science Center at Houston where she graduated with honors. She then went on to earn a Master of Business Administration from Our Lady of the Lake University in San Antonio, TX. Yvette has also completed postgraduate work in Epidemiology at Walden University.

Norman B. Purvis

Head of ChemoINTEL and ImmunoINTEL
PhD

{ View Bio }

Dr. Norman Purvis is equal parts scientist and entrepreneur.

With ten patents and dozens and published articles, Norman is well-recognized as a thought leader in quantitative fluorescence techniques and standardization practices for high complexity flow cytometric assay design, validation and implementation. Leveraging his years of experience in academia and business, Norman is well-versed in bringing commercially viable products to market.

With significant experience in GLP and CLIA regulatory environments, Norman specializes in developing custom quantitative assays to support drug discovery and clinical trials – adhering to GLP requirements.

As an experienced leader managing cross-functional teams, Norman has played pivotal roles at many biopharma companies including Nodality and IncellDx, directing manufacturing personnel, research associates and scientists in support of R&D.